An increase in plasma phenylalanine level along with a decrease in plasma malate level of HER2-positive breast cancer patients 2 weeks after completion of doxorubicin treatment indicated an abnormality of phenylalanine metabolism [49]. Here, ERBB2 is linked to breast cancer.